Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ThromboGenics
ClinicalTrials.gov Identifier:
NCT00798317
First received: November 25, 2008
Last updated: April 4, 2014
Last verified: April 2014
  Purpose

This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.


Condition Intervention Phase
Vitreomacular Adhesion
Drug: Ocriplasmin 125µg
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion.

Resource links provided by NLM:


Further study details as provided by ThromboGenics:

Primary Outcome Measures:
  • Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
    Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at Day 28, as determined by masked Central Reading Centre (CRC) Optical Coherence Tomography(OCT)evaluation.


Secondary Outcome Measures:
  • Proportion of Subjects With Total Posterior Vitreous Detachment (PVD) at Day 28 [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
    Proportion of subjects with total PVD at Day 28, as determined by masked investigator assessment of B-scan ultrasound.


Enrollment: 326
Study Start Date: December 2008
Study Completion Date: July 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ocriplasmin 125µg
125µg of ocriplasmin intravitreal injection
Drug: Ocriplasmin 125µg
125µg of ocriplasmin intravitreal injection
Other Name: Microplasmin
Placebo Comparator: Placebo
Intravitreal injection of placebo
Drug: Placebo
Intravitreal injection placebo.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence of focal vitreomacular adhesion (i.e., central vitreal adhesion within 6 mm Optical Coherence Tomography (OCT) field surrounded by elevation of the posterior vitreous cortex) that in the opinion of the Investigator is related to decreased visual function (such as metamorphopsia, decreased visual acuity, or other visual complaint)

Exclusion Criteria:

  • Any evidence of proliferative retinopathy (including Proliferative Diabetic Retinopathy (PDR)) or other ischemic retinopathies involving vitreoretinal vascular proliferation) or exudative Age-Related Macular Degeneration (AMD) or retinal vein occlusion in the study eye
  • Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye
  • Subjects with macular hole diameter > 400 µm in the study eye
  • Aphakia in the study eye
  • High myopia (more than 8D) in study eye (unless prior cataract extraction or refractive surgery that makes refraction assessment unreliable for myopia severity approximation, in which case axial length >28 mm is an exclusion).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798317

  Hide Study Locations
Locations
United States, California
Retinal Diagnostic Center
Campbell, California, United States, 95008
West Coast Retina Group, Inc
San Francisco, California, United States, 94107
California Retina Consultants
Santa Barbara, California, United States, 93103
United States, Florida
Medeye
Miami, Florida, United States, 33143
Retina Specialists
Pensacola, Florida, United States, 32503
United States, Kentucky
Paducah Retinal Center
Paducah, Kentucky, United States, 42001
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
United States, Missouri
Vision Research Center at Truman Medical Center
Kansas City, Missouri, United States, 64108
United States, New Jersey
Deleware Valley Retina Associates
Lawrenceville, New Jersey, United States, 08648
United States, New York
Capital Region Retina
Albany, New York, United States, 12206
United States, North Carolina
Southeast Clinical Research Assoicates, PA
Charlotte, North Carolina, United States, 28210
United States, Oklahoma
Dean A McGee Eye Institute
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Scheie Eye Institute, Penn Eye Care
Philadelphia,, Pennsylvania, United States, 19104
United States, South Dakota
Black Hils regional Eye Institute
Rapid City, South Dakota, United States, 57701
United States, Texas
Texas Retina Associates
Arlington, Texas, United States, 76012
Retina Research Center
Austin, Texas, United States, 78705
Retina Consultants
Fort Worth,, Texas, United States, 76104
Medical Center Ophthalmology Assoc.
San Antonio, Texas, United States, 78240
Eye Care Associates
Tyler, Texas, United States, 75701
United States, Washington
Vitreoretinal Associates
Seattle, Washington, United States, 98104
Belgium
University Hospital Leuven
Leuven, Belgium
Czech Republic
University Hospital Brno
Brno, Czech Republic, 625 00
University Hospital Hradec Kralove
Hradec Kralove, Czech Republic, 500 05
University Hospital Olomouc
Olomouc, Czech Republic, 775 20
Central Military Hospital
Prague, Czech Republic, 169 02
University Hospital Kralovske Vinohrady
Prague, Czech Republic, 100 34
Gemini Eye Clinic
Zlin, Czech Republic, 760 01
Germany
Augenklinik-Universität Bonn
Bonn, Germany, D-53127
St. Joseph Stift Bremen Abteilung für Augenheilkunde
Bremen, Germany, 28209
Universitäts-Augenklinik Frankfurt am Main
Frankfurt, Germany, 60590
Städtische Kliniken Frankfurt am Main, Klinik für Augenheilkunde
Frankfurt am Main, Germany, 65929
Universität Göttingen
Göttingen, Germany, 37075
Klinik und Poliklinik für Augenheilkunde
Leipzig, Germany, 04103
Philipps Universität Marburg
Marburg, Germany, 35037
Augenklinik der Ludwig Maximilians Universität München
München, Germany, 80336
Augenärzte am St. Franziskus Hospital
Münster, Germany, 48145
Augenklinik im Dietrich-
Neubrandenburg, Germany, 17036
Poland
Indywidualna Specjalistyczna Praktyka Prywatna
Gdansk, Poland, 80-147
Oddział Okulistyczny OSK,
Katowice, Poland, 40-760
Spain
Instituto Oftalmología de Alicante (Vissum)
Alicante, Spain, 03016
Centro Teknon-Institut de la Macula i de la Retina
Barcelona, Spain, 08022
Hospital La Paz
Madrid, Spain, 28046
Instituto Technologico de Oftalmologia S.L
Santiago de Compostela, Spain, 15705
Hospital General de Valencia
Valencia, Spain, 46014
United Kingdom
St Paul's Eye Unit
Liverpool, United Kingdom, L7 8XP
Moorfields Eye Hospital
London, United Kingdom, EC1V 2PD
Southampton Eye Unit, Southampton General Hospital
Southampton, United Kingdom, SO16 6YD
Wolverhampton Eye Infirmary-New Cross Hospital
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
ThromboGenics
  More Information

No publications provided by ThromboGenics

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ThromboGenics
ClinicalTrials.gov Identifier: NCT00798317     History of Changes
Other Study ID Numbers: TG-MV-007
Study First Received: November 25, 2008
Results First Received: December 20, 2012
Last Updated: April 4, 2014
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Poland: Ministry of Health
Portugal: National Pharmacy and Medicines Institute
Spain: Spanish Agency of Medicines
United States: Food and Drug Administration

Additional relevant MeSH terms:
Tissue Adhesions
Cicatrix
Fibrosis
Pathologic Processes

ClinicalTrials.gov processed this record on August 21, 2014